Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma

Investigators evaluated responses to brentuximab vedotin (BV)+ pembrolizumab after PD-1 therapy and explored corresponding biomarkers. A total of 58 patients with metastatic cutaneous melanoma received ≥1 dose of BV + pembrolizumab.